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Objective: Targeted therapy promises to improve patient outcome in non–small cell lung cancer. Biomarkers can
direct targeted therapy toward patients who are most likely to respond, thus optimizing benefit. A novel agent with
antineoplastic potential is the glucose analog, 2-deoxyglucose. 2-Deoxyglucose targets tumor cells, owing to their
increased glucose uptake, inhibiting cellular metabolism and inducing energetic stress, resulting in decreased cel-
lular viability. The tumor suppressor LKB1 is activated by energetic stress, and cells that lack LKB1 fail to re-
spond and undergo cell death, suggesting that LKB1-null non–small cell lung cancer may have an increased
susceptibility to 2-deoxyglucose. Inasmuch as somatic loss of LKB1 is a frequent event in non–small cell lung
cancer, LKB1 expression could be used as a biomarker for directing 2-deoxyglucose therapy in patients with
this type of cancer.
Methods: LKB1-positive and LKB1-negative non-small cell lung cancer cell lines were evaluated for cell via-
bility, markers of apoptosis, and gene expression after 2-deoxyglucose treatment and compared with vehicle con-
trol.
Results: LKB1-negative cells treated with 2-deoxyglucose displayed a significant decrease in cell viability com-
pared with LKB1-positive cells. Gene expression profiles of 2-deoxyglucose treated cells revealed changes in
apoptotic markers in LKB1-negative cells, correlating with activation of apoptosis. Re-expression of LKB1 pre-
vented 2-deoxyglucose mediated apoptosis, demonstrating the critical role of LKB1 in mediating 2-deoxyglucose
toxicity.
Conclusions: LKB1 loss increases susceptibility to 2-deoxyglucose treatment in non-small cell lung cancer lines,
even at low doses. Thus, determination of LKB1 status may help direct therapy to those patients most likely to
benefit from this novel approach, making it useful in the treatment of patients with non-small cell lung cancer.
General Thoracic Surgery Inge et alAlthough recent statistics reveal significant increases in sur-
vival for many cancers, survival rates for lung cancer have
seen little improvement over the past few decades, with
overall patient 5-year survival approximately 15%.1 Cur-
rently, curative treatment of non–small cell lung cancer
(NSCLC) is restricted to surgical resection for very early dis-
ease, with the addition of systemic chemotherapy for pa-
tients with later stages of cancer, inasmuch as metastatic
recurrence is common. Unfortunately, the response rates
for NSCLC to traditional chemotherapeutic agents has
been poor, although the more recent attempts at personaliz-
ing chemotherapy appear to hold promise for improving out-
comes. Certainly, the understanding of epidermal growth
factor receptor (EGFR) mutations in some cancers has
helped direct application of tyrosine kinase inhibitors toward
patients with these distinct mutations.2 The success of this
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of each individual cancer can be exploited to improve out-
comes for the disease. Thus, the paradigm in lung cancer
is changing toward one of personalized therapy. The
LKB1 tumor suppressor gene, which is commonly mutated
in NSCLC, offers one such opportunity.
The LKB1 gene was discovered through genetic linkage
analysis of the familial disorder, Peutz–Jeghers syndrome3
and has since been found to be inactivated in 30% to 50%
of patients with NSCLC,4-6 about twice the prevalence of
EGFR mutations found in this disease. Further, convergent
in vitro and in vivo studies have led to the realization that
loss of LKB1 may be a critical event in NSCLC.6-9 LKB1
is a serine–threonine kinase, phosphorylating and regulating
14 different protein kinases.3 The biological role of LKB1
regulation of these kinases remains largely unknown except
for the adenosine monophosphate (AMP)–activated protein
kinase, or AMPK. The primary function of LKB1–AMPK
signaling is in the regulation of cellular energy metabolism.
Increases in intracellular levels of AMP, caused by hypoxia,
ischemia, or other stressors, induce the LKB1-dependent ac-
tivation of AMPK, allowing AMPK to alter cellular func-
tions and restore adenosine triphosphate levels within the
cell.3,9 One such process regulated by AMPK during low en-
ergy states is cell growth.10 Inasmuch as deregulation of cell
growth is a critical feature of cancer, this function of LKB1
and AMPK has led to an increased interest in their roles inrgery c March 2009
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SAbbreviations and Acronyms
AMP ¼ adenosine monophosphate
AMPK ¼ AMP-activated protein kinase
2-DG ¼ 2-deoxyglucose
EGFR ¼ epidermal growth factor receptor
KDLKB1 ¼ kinase-dead LKB1
mTOR ¼ mammalian target of rapamycin
NSCLC ¼ non–small cell lung cancer
PARP ¼ poly (ADP-ribose) polymerase
TBST ¼ Tris buffered saline/0.1% Tween 20
TSC1/2 ¼ tuberous sclerosis complex
malignancy. LKB1 and AMPK negatively affect cell growth
by inhibition of the protein kinase, mTOR (mammalian tar-
get of rapamycin), which functions in increasing cell growth
and is commonly deregulated in cancer.11 LKB1–AMPK
regulation of mTOR occurs via AMPK activation of the tu-
berous sclerosis complex (TSC1/2) tumor suppressors,
which inhibit mTOR activation.10,12 Interestingly, stimuli
that normally activate LKB1–AMPK fail to result in de-
creased mTOR activity in LKB1-null cells12-14 and can acti-
vate apoptosis (Figure 1). These and other findings have
established a direct link between the LKB1–AMPK and
the mTOR signaling pathways.
During the 1920s, Otto Warburg made the discovery that
tumor cells rely on glycolysis, as opposed to normal mito-
chondrial oxidative phosphorylation, for energy production
(the ‘‘Warburg effect’’).9 Recent work in basic and clinical
research has improved this basic understanding, demonstrat-
ing that tumor cells have uniquely altered metabolisms, dis-
playing increased glucose uptakes, increases in enzymes of
the glycolytic pathway, and an increased sensitivity to inhi-
bition of glycolysis.9 The increased uptake of glucose and
lack of glucose-6-phosphatase activity (which directs glu-
cose exit from the cancer cell) has led to the clinical use of
the glucose analog [18F] fluoro-deoxyglucose, in positron
emission tomography scanning. Another glucose analog,
2-deoxyglucose (2-DG), inhibits glycolysis and appears to
be preferentially toxic to tumor cells.15-17 Studies have
found that 2-DG has potential in treating cancer and is being
investigated currently in phase I trials. It is also being ex-
plored as a treatment for epilepsy as a surrogate for the ‘‘ke-
togenic diet,’’18 and it appears to be well tolerated in early
studies. Fortuitously, and of significant importance, 2-DG
is also a specific activator of LKB1–AMPK signaling, sug-
gesting that LKB1–AMPK may be critical in mediating the
antitumor effects of 2-DG.
In this study, we examined the response of NSCLC cell
lines to the glycolytic inhibitor 2-DG and the relationship
of the response to the function of the LKB1 tumor suppres-
sor gene. We hypothesized that loss of LKB1 functionThe Journal of Thoracic andwould render NSCLC cancer cell lines more susceptible to
glycolytic stress. If true, this would provide a unique oppor-
tunity to identify future patients with NSCLC who would be
susceptible to 2-DG therapy in the clinical setting.
METHODS
Reagents and Cell Culture
H23, H2009, H2122, and H441 lung adenocarcinoma cell lines were ob-
tained from ATCC (Manassas, Va) and maintained in RPMI 1640 (Invitro-
gen, Carlsbad, Calif)/10% fetal bovine serum under standard tissue culture
conditions. Antibodies to LKB1, phosphorylated AMPK, AMPK, and
cleaved poly (ADP-ribose) polymerase (PARP) were purchased from Cell
Signaling Technology (Danvers, Mass). CellTiter Blue and Caspase-Glo
3/7 kits were purchased from Promega (Madison, Wis). 2-DG was pur-
chased from Sigma Chemical Co (St Louis, Mo) and diluted to a 1-mol/L
stock in sterile phosphate-buffered saline. The pBABE retroviral constructs
containing FLAG-tagged full-length LKB1 and the KDLKB1 originated in
Dr Lewis Cantley’s laboratory (Harvard Medical School, Boston, Mass) and
were obtained from Addgene.org (Cambridge, Mass).
Cell Lysis and Immunoblotting
Cells were incubated on ice for 30 minutes with a lysis buffer containing
10 mmol/L Tris–HCl, 150 mmol/L NaCl, and 1% IGEPAL (Sigma). Imme-
diately before use, a protease inhibitor cocktail (Sigma) and phosphatase
cocktails I and II (Sigma) were added to the lysis buffer. Lysates were trans-
ferred to tubes and insoluble material was pelleted by centrifugation. Protein
concentration was determined by the Bio-Rad DC protein kit (Bio-Rad
Laboratories, Hercules, Calif). For immunoblotting, 100 mg of total protein
lysate was separated by sodium dodecyl-sulfate–polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose. Blots were blocked in 5%
milk/Tris buffered saline/0.1% Tween 20 (TBST) and primary antibodies
were diluted in 5% bovine serum albumin (Sigma)/TBST and incubated
overnight at 4C. Blots were developed with Amersham ECL Plus
(GE Healthcare, Waukesha, Wis) and visualized on a Kodak Image station.
Cell Viability
Cell lines were plated at a density of 2500 cells per well in 96 well plates.
After attachment, 2-DG was diluted in media at indicated concentrations
FIGURE 1. LKB1-AMPK signaling and regulation of mammalian target
of rapamycin (mTOR). TSC, tuberous sclerosis complex; AMPK, adenosine
monophosphate kinase.Cardiovascular Surgery c Volume 137, Number 3 581
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Sand added to wells. Treatment was carried out for 48 hours in standard cell
culture conditions, before cell viability was assessed by the CellTiter Blue
kit (Promega) according to manufacturer instructions and read on a Beckman
Coulter DTX 880. The percentage of viable cells was determined by nor-
malizing treated samples to vehicle (phosphate-buffered saline).
Caspase 3/7 Activity
Cell lines were plated at a density of 5000 cells per well in 96 well plates.
After attachment, cells were treated with either 2-DG or vehicle for 24
hours. Activity of caspases 3 and 7 was determined by a Caspase-Glo 3/7
kit (Promega) according to manufacturer instructions and scanned with
a Beckman Coulter DTX 880 plate reader (Beckman Coulter, Fullerton,
Calif). Relative light units from treated samples were normalized to vehicle
controls to generate fold activity of caspases 3 and 7.
FIGURE 2. Effect of 2-DG in LKB1-null and LKB1-expressing NSCLC
cells. A, Immunoblot of LKB1 in H23, H2122, H2009, and H441 NSCLC
cell lines. GAPDH was used as a loading control. B, Induction of AMPK
phosphorylation by 2-DG. LKB1-positive (H2009, H441) and LKB1-neg-
ative (H23, H2122) cell lines were treated with 20 mmol/L of 2-DG for 1
hour. Protein lysates were immunoblotted with an antibody specific to phos-
phorylated Thr172 AMPK. Note 2-DG induces phosphorylation at Thr172
only in LKB1-expressing cells. Both AMPK and GAPDH were used as
loading controls. Blot is representative of two independent experiments.
C, LKB1 null NSCLC cell are more sensitive to 2-DG. NSCLC cell lines
were treated for 48 hours with indicated concentrations of 2-DG. Bars rep-
resent standard error. GAPDH, Glyceraldehyde-3-phosphate dehydroge-
nase; 2-DG, 2-deoxyglucose; AMPK, adenosine monophosphate activated
protein kinase; P-AMPK, adenosine monophospahte kinase phosphoryla-
tion.582 The Journal of Thoracic and Cardiovascular SurGene Expression Profiling
Total RNA was extracted from cells using TRIzol (Invitrogen) followed
by RNeasy Mini Kit purification (Qiagen, Venlo, Netherlands) according to
manufacturer specifications. Spectrophotometric analysis was performed on
a NanoDrop ND-1000 (Thermo Scientific, Waltham, Mass) and RNA qual-
ity was assessed on a BioAnalyzer 2100 (Agilent, Santa Clara, Calif) using
strict RNA integrity QC cutoffs. Next, 500 ng of RNA was labeled and hy-
bridized (in duplicate) to Agilent 4 3 44K Whole Human Genome One-
Color Oligo Microarrays according to manufacturer specifications. Slides
were scanned using the Agilent Microarray Scanner (model G2505B) and
processed with Agilent’s Feature Extraction software (v. 9.5.1). Compara-
tive and statistical analyses for gene expression profiles were carried out
with GeneSpring 7.3 software (Silicon Genetics, Inc, Redwood City, Calif).
Apoptosis-related genes of interest were identified by key word search (‘‘ap-
optosis’’) followed by unsupervised hierarchical clustering. Significance
values were determined by comparing expression of all LKB1-positive sam-
ples (grouped) to all LKB1-negative samples (grouped) for each gene using
the Student t test and a P<.05 cutoff after multiple testing correction using
the false discovery rate method.
RESULTS
To investigate the role of LKB1 in the effectiveness of 2-
DG treatment, we screened four NSCLC cell lines (H23,
H2122, and H441, H2009) by immunoblot for LKB1 ex-
pression (Figure 2, A). Exposure of cells to 20 mmol/L of
2-DG induced LKB1-dependent activation of AMPK, con-
firming published data (Figure 2, B). Inasmuch as LKB1–
AMPK signaling can affect cell growth or cell number, we
compared the number of viable LKB1-null and LKB1-pos-
itive cells after treatment with 2-DG for a range of concen-
trations over time. After 48 hours of treatment, both
LKB1-positive and LKB1-negative cells showed a signifi-
cant decrease in cell viability at high doses (20 mmol/L)
of 2-DG (Figure 2, C), thus confirming the ability of 2-DG
to limit cell number. However, LKB1-null cells showed
a significant decrease in cell viability for all doses tested,
even at the lowest dose (2.5 mmol/L) compared with
LKB1-positive cells (P ¼ 5.73 $ 1013). These findings sug-
gested that LKB1-null NSCLC cells are significantly more
sensitive to treatment with 2-DG than LKB1-positive cells
and that 2-DG might induce a different response in LKB1-
null NSCLC cells.
Activation of energetic stress by glucose starvation re-
sults in the induction of apoptosis or programmed cell death
in both LKB1-null NSCLC cells and LKB1-null mouse
embryonic fibroblasts.12-14 Inasmuch as 2-DG had a more
significant effect on cell viability in LKB1-null but not
LKB1-positive NSCLC cell lines, we hypothesized that
2-DG might alternately induce apoptotic pathways in
LKB1-null cell lines, reducing cell number. To test this hy-
pothesis, we compared apoptosis-related transcripts of H23
(LKB1-null) and H2009 (LKB1-positive) cells by treatment
with either low-dose (2.5 mmol/L) or high-dose (20 mmol/
L) 2-DG or vehicle (phosphate-buffered saline) for 6 hours
followed by microarray-based assessment of gene expres-
sion. Expression analysis revealed dramatic changes ingery c March 2009
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SFIGURE 3. Microarray analysis of LKB1-positive (LKB1þ) or LKB1-negative (LKB1) NSCLC cell lines (H2009 and H23, respectively) treated or un-
treated, in a dose-dependent manner, with 2-DG. Unsupervised hierarchical clustering was performed on 117 apoptosis-related transcripts (left). Excerpted
gene clusters are shown at the right. The pattern of gene expression reflects an activation of apoptosis in LKB1-negative cells. Italicized, bolded genes are
discussed in the text. 2-DG, 2-Deoxyglucose.a variety of genes owing to 2-DG treatments in both H2009
and H23 (Figure 3). Interestingly, although we found little
difference in expression of the pro-apoptotic protein, Fas li-
gand, and its related proteins, we observed dose-dependent
changes in the expression of the anti-apoptotic protein,
BCL-2, and several BCL-2 interacting proteins in LKB1-
null H23 cells (Figure 3). Taken together, these results sug-
gested an activation of apoptosis within H23 LKB1-null
NSCLC cells, but not H2009 cells, by 2-DG. To confirm
that 2-DG activated apoptosis in LKB1-null, but not
LKB1-positive NSCLC cells, H23 and H2009 were treated
with increasing doses of 2-DG for 24 hours and assayed forThe Journal of Thoracic and Cactivation of caspases 3 and 7. Treatment with 2-DG in-
duced a dose-dependent activation of caspases 3 and 7 in
H23 cells, consistent with the gene expression data (Fig-
ure 4, A). Further, immunoblot analysis of cleaved PARP,
a marker of apoptosis, was present in 2-DG–treated H23
cells, but not in H2009 cells (Figure 4, B). Thus, these find-
ings demonstrate that 2-DG induces apoptosis in LKB1-
null but not in LKB1-positive cells.
To understand whether the lack of LKB1 function was
responsible for the effects of 2-DG on NSCLC cells, we
re-introduced a FLAG-tagged LKB1 into H23 cells via ret-
roviral infection. In addition, an inactive, kinase-dead formardiovascular Surgery c Volume 137, Number 3 583
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SFIGURE 4. 2-DG induces apoptosis in LKB1-null NSCLC cells. A, Activity of caspases 3 and 7 in NSCLC cells after 24 hours of 2-DG treatment at the
indicated concentrations. Bars represent standard error and experiment was repeated twice. B, Immunoblot of cleaved PARP. H23 and H2009 cells were
treated for 24 hours with 20 mmol/L of 2-DG. Note presence of cleaved PARP in H23, but not H2009 cells. GAPDH was used as a loading control. C,
Immunoblot of LKB1 and KDLKB1 in H23 cells after retroviral infection and puromycin selection. GAPDH was used as a loading control. D, 2-DG acti-
vation of LKB1 in H23-LKB1, but not H23-KDLKB1 cells. Blot was stripped and probed for AMPK as a loading control. Blot represents two independent
experiments. E, LKB1, but not KDLKB1, prevents activation of capase 3 and 7 in H23 cells. H23–LKB1 and H23–KDLKB1 cells were treated for 24 hours
with 20 mmol/L 2-DG before analysis as described in Materials and Methods. Bars represent standard error and experiment was repeated twice. F, Immu-
noblot of cleaved PARP in H23–LKB1 and H23–KDLKB1 after treatment with 20 mmol/L of 2-DG for 24 hours. Blot is representative of two independent
experiments. GAPDH was used as a loading control. 2-DG, 2-Deoxyglucose; PARP, poly (ADP-ribose) polymerase; AMPK, adenosine monophosphate
activated protein kinase; KD-LKB1, kinase-dead LKB1.of LKB1 (KDLKB1) was also introduced using the same ret-
roviral vector as a negative control. H23 cells were infected
with either FLAG-tagged LKB1 or KDLKB1 retroviruses
and underwent puromycin selection. The resulting cell lines,
H23–LKB1 and H23–KDLKB1, both express LKB1, as
shown by Western blot (Figure 4, C). However, only
H23–LKB1 is capable of phosphorylating AMPK when
treated with 2-DG, whereas H23–KDLKB1 does not (Fig-
ure 4, D). Re-expression of LKB1 in H23 cells prevented
2-DG–induced activation of caspase 3 and 7, but not in
H23 cells expressing KDLKB1 (Figure 4, E). In addition,
re-expression of LKB1 in H23 cells also prevented cleavage
of PARP after treatment with 2-DG, but not in H23–584 The Journal of Thoracic and Cardiovascular SurKDLKB1 cells (Figure 4, F). In sum, these findings demon-
strate that LKB1 function is critical in determining the ef-
fects of 2-DG in NSCLC cells.
DISCUSSION
Directing therapy based on the unique characteristics of
each individual’s cancer (personalized therapy) has many
potential benefits. The recent identification of unique
EGFR mutations in some NSCLCs has led to the more effec-
tive use of EGFR inhibitors.2 It is clear that biological ap-
proaches to lung cancer have the potential to affect the
overall survival from this disease, which historically has
lagged behind the success of treatment for cancers of othergery c March 2009
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tics of a cancer has led to attempts at improving the out-
comes of traditional chemotherapeutic agents by directing
these agents to those cancers most likely to respond.19,20
Currently, the molecular diversity of NSCLC and the com-
plexity of its response to traditional agents suggest that suc-
cess in improving the outcomes for this disease will rely in
part on individualized therapy. To this end, we have attemp-
ted to exploit the frequent inactivation of LKB1 in NSCLC
to design a potential therapy for patients with these tumors.
LKB1 appears to be inactivated/mutated in up to 50% of
NSCLC,8 representing a large group of patients who could
benefit from this therapy. Inasmuch as LKB1 is associated
with the regulation of cellular metabolism, we hypothesized
that a glycolytic inhibitor such as 2-DG could interfere with
the survival of cells with inactive LKB1.
We found that 2-DG was a potent activator of apoptosis in
LKB1-null cells, which confirms previous studies that have
demonstrated activation of apoptosis after induction of ener-
getic stress in LKB1-null cells.12-14 The 2-DG–dependent
activation of apoptosis was prevented by re-expression of
LKB1 in LKB1-null cells, highlighting the critical role of
LKB1 in metabolic adaptation. During conditions of re-
duced nutrient availability, cells enter into either autophagy,
a process in which energy is derived via catabolism of intra-
cellular organelles, or apoptosis.21,22 LKB1 activity appears
to play a role in this decision, as stabilization of the cell cycle
inhibitor, p27/kip1, by LKB1 results in autophagy, instead
of apoptosis during energetic stress.23 Thus, 2-DG treatment
may result in autophagy in LKB1-expressing NSCLC cells,
an area we are currently investigating. However, other regu-
latory functions of LKB1 cannot be discounted inasmuch as
inhibition of mTOR with rapamycin can also prevent cell
death during energetic stress in LKB1-null cells,12,14 while
we have observed increased mTOR activation in LKB1-
null cells treated with 2-DG (unpublished observations).
These findings suggest that the inability to regulate mTOR
activity in LKB1-null cells during treatment with 2-DG
may result in apoptosis owing to undetermined mechanisms.
We are currently investigating these and other possible
mechanisms for 2-DG toxicity in LKB1-null NSCLC cells.
Gene expression analysis revealed dose-dependent
changes in BCL-2 and BCL-2–related genes in LKB1-
null cells, as well as activation of caspases and caspase
function (see Figures 3 and 4), suggesting that LKB1-null
cells undergo apoptosis via a mitochondrion-mediated
mechanism. Surprisingly, we also observed changes in ap-
optotic and inflammatory genes in LKB1-expressing cells
with 2-DG treatment (specifically, interleukin 1; see Fig-
ure 3). The increases in these genes suggest that although
these cells did not undergo apoptosis in our in vitro system,
it is possible that in vivo, the expression of these genes may
induce recruitment of inflammatory cells, which might acti-
vate apoptosis through receptor-mediated pathways. Alter-The Journal of Thoracic andnatively, cells in extended periods of autophagy undergo
cell death via nonapoptotic type II pathway,21,22 which can-
not be determined by our experimental design and could
generate our observed decreases in cell viability in LKB1-
expressing NSCLC after 2-DG treatment (Figure 2, C).
Thus, it is of critical importance to extend these studies
into in vivo models, as well as studying the effects of 2-
DG on LKB1-expressing NSCLC cells, areas that we are
actively pursuing.
2-DG is currently undergoing phase I trials in combina-
tion with standard chemotherapeutics for the treatment of
various solid tumors. Our work suggests that categorizing
patients on the basis of LKB1 expression will yield im-
proved patient response to 2-DG. This treatment paradigm
is similar to the use of EGFR inhibitor, Tarceva, in NSCLC
patients with distinct mutations within EGFR, which occur
in only 10% to 15% of patients with NSCLC.2 Current sta-
tistics have suggested LKB1 loss may occur in 30% to 50%
of NSCLC. However, NSCLC is a heterogeneous disease
consisting of large cell carcinoma, adenocarcinoma, squa-
mous cell carcinoma, and mixed histology tumors (adenos-
quamous). Among these subtypes, LKB1 loss appears to
occur most frequently in adenocarcinoma (34%), with
LKB1 loss occurring in squamous cell carcinoma (19%),
large cell carcinoma (14%), and adenosquamous (25%) at
lower rates.8 On the basis of these findings, we initially
chose to focus our studies on adenocarcinoma cell lines.
However, it is plausible that 2-DG would induce a similar
response in squamous cell, large cell, and adenosquamous
tumors, a subject currently under investigation in our labora-
tory. Despite the variances of LKB1 loss within the NSCLC
subtypes, 2-DG would benefit a substantially larger patient
population than would Tarceva-sensitive NSCLC. Owing
to the significant lack of treatment options available to pa-
tients with NSCLC, we believe that the targeting of meta-
bolic processes within LKB1-null NSCLC tumor will
provide a new avenue for treatment in this disease.
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